A analysis staff led by brain science professor Um Ji-won at Daegu Gyeongbuk Institute of Science and Technology (DGIST) has recognized for the primary time on this planet how a organic switch in brain immune cells can ease Alzheimer’s illness, providing a possible pathway to repurpose current medication.
Daegu Gyeongbuk Institute of Science and Technology (DGIST) professor Um Ji-won / Courtesy of DGIST
The examine revealed that the brain’s somatostatin, a neuropeptide that dampens neural exercise and instantly regulates microglia, that are resident immune cells within the brain, shifting them right into a protecting state that reduces illness pathology.
When microglia had been handled with somatostatin, their potential to clear poisonous waste surged whereas inflammatory indicators sharply declined, suggesting that the peptide successfully places brain immunity again in stability.
“This study is the first to show that the brain neurotransmitter somatostatin can directly reset immune cell states to ease dementia pathology and even improve memory performance,” the professor stated.
Alzheimer’s illness is marked by the buildup of sticky protein clumps build up within the brain, often called amyloid‑beta plaques, and continual neuroinflammation pushed by overactivated microglia. While these cells initially assist clear poisonous proteins, they’ll later turn into hyperactive, releasing inflammatory elements that injury synapses and speed up cognitive decline.
Um’s staff discovered that somatostatin acts as a key modulator of this course of. In experiments utilizing Alzheimer’s illness mannequin mice, boosting somatostatin ranges suppressed neuroinflammation and considerably decreased amyloid‑beta plaques.
The handled mice additionally confirmed a statistically important enchancment in spatial reminiscence, demonstrating that the impact goes past the mobile degree to actual cognitive restoration.
“So far, research on neurodegenerative diseases has focused mainly on neurons, but this study shows that a neuropeptide can directly reset the state of microglia, allowing integrated control of both neuroinflammation and amyloid pathology,” the analysis staff stated.
“Building on this, it should be possible to design next‑generation brain disease and neuroinflammation therapies that precisely target specific state changes in microglia.”
It famous that somatostatin receptor agonists used within the experiments are already authorized by the U.S. Food and Drug Administration for different circumstances, equivalent to acromegaly. This raises the potential for accelerating Alzheimer’s remedy growth via repurposing current compounds and increasing into new remedy methods.
The staff stated its final objective is to construct a brand new framework for remedy that treats synapses and their immune setting as a single, built-in system. By decoding how microglia and different exterior regulators reshape synaptic perform, they hope to pinpoint drug targets that may truly halt the development of laborious‑to‑deal with neurodegenerative and psychiatric ailments.